Cargando…

Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression

BACKGROUND: Biochemical recurrence is defined as only rising CA-125 but no radiographic evidence of disease; noteworthily, it generally precedes the onset of clinical evidence. Now treatment strategies of biochemical recurrence ovarian cancer (OC) remain controversial. Apatinib as monotherapy or in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhongyu, Huang, Yake, Long, Ling, Zhou, Li, Huang, Yan, Gan, Lei, Pu, Aimin, Li, Sufen, Xie, Rongkai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274012/
https://www.ncbi.nlm.nih.gov/pubmed/34247630
http://dx.doi.org/10.1186/s13048-021-00843-8
_version_ 1783721484976390144
author Wang, Zhongyu
Huang, Yake
Long, Ling
Zhou, Li
Huang, Yan
Gan, Lei
Pu, Aimin
Li, Sufen
Xie, Rongkai
author_facet Wang, Zhongyu
Huang, Yake
Long, Ling
Zhou, Li
Huang, Yan
Gan, Lei
Pu, Aimin
Li, Sufen
Xie, Rongkai
author_sort Wang, Zhongyu
collection PubMed
description BACKGROUND: Biochemical recurrence is defined as only rising CA-125 but no radiographic evidence of disease; noteworthily, it generally precedes the onset of clinical evidence. Now treatment strategies of biochemical recurrence ovarian cancer (OC) remain controversial. Apatinib as monotherapy or in combination with other chemotherapeutic agents has shown its effect in the treatment of some advanced malignancies. In our study, we focused on the efficacy of apatinib in recurrent OC, especially its clinical activity in biochemical-only recurrent OC patients. METHODS: We retrospectively analyzed clinical material of 41 recurrent patients who had received apatinib monotherapy or apatinib plus chemotherapy between June 2016 and August 2018. Apatinib was administered at a 500mg daily dose. Response was determined according to measurable disease or serum carbohydrate antigen (CA)-125 levels. Progression-free survival (PFS) was estimated by Kaplan–Meier method. RESULTS: All patients were evaluable, 19 (46.34%) had biochemical relapse and 22 (53.66%) had clinical relapse. The objective response rate (ORR) and disease control rate (DCR) in the overall population were 31.71% and 78.05%, respectively. The median PFS was 7 months (95% confidence interval 5.43–8.57). And in patients with biochemical-only relapse, the median PFS was 6 months, with ORR of 26.32% and DCR of 89.47%. CONCLUSIONS: Apatinib is a well-tolerated and effective agent to delay clinical progression of patients with biochemical-only recurrent OC. More important, our study shows the promising prospect for treating OC patients with asymptomatic biochemical relapse.
format Online
Article
Text
id pubmed-8274012
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82740122021-07-13 Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression Wang, Zhongyu Huang, Yake Long, Ling Zhou, Li Huang, Yan Gan, Lei Pu, Aimin Li, Sufen Xie, Rongkai J Ovarian Res Research BACKGROUND: Biochemical recurrence is defined as only rising CA-125 but no radiographic evidence of disease; noteworthily, it generally precedes the onset of clinical evidence. Now treatment strategies of biochemical recurrence ovarian cancer (OC) remain controversial. Apatinib as monotherapy or in combination with other chemotherapeutic agents has shown its effect in the treatment of some advanced malignancies. In our study, we focused on the efficacy of apatinib in recurrent OC, especially its clinical activity in biochemical-only recurrent OC patients. METHODS: We retrospectively analyzed clinical material of 41 recurrent patients who had received apatinib monotherapy or apatinib plus chemotherapy between June 2016 and August 2018. Apatinib was administered at a 500mg daily dose. Response was determined according to measurable disease or serum carbohydrate antigen (CA)-125 levels. Progression-free survival (PFS) was estimated by Kaplan–Meier method. RESULTS: All patients were evaluable, 19 (46.34%) had biochemical relapse and 22 (53.66%) had clinical relapse. The objective response rate (ORR) and disease control rate (DCR) in the overall population were 31.71% and 78.05%, respectively. The median PFS was 7 months (95% confidence interval 5.43–8.57). And in patients with biochemical-only relapse, the median PFS was 6 months, with ORR of 26.32% and DCR of 89.47%. CONCLUSIONS: Apatinib is a well-tolerated and effective agent to delay clinical progression of patients with biochemical-only recurrent OC. More important, our study shows the promising prospect for treating OC patients with asymptomatic biochemical relapse. BioMed Central 2021-07-12 /pmc/articles/PMC8274012/ /pubmed/34247630 http://dx.doi.org/10.1186/s13048-021-00843-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Zhongyu
Huang, Yake
Long, Ling
Zhou, Li
Huang, Yan
Gan, Lei
Pu, Aimin
Li, Sufen
Xie, Rongkai
Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
title Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
title_full Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
title_fullStr Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
title_full_unstemmed Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
title_short Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
title_sort apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274012/
https://www.ncbi.nlm.nih.gov/pubmed/34247630
http://dx.doi.org/10.1186/s13048-021-00843-8
work_keys_str_mv AT wangzhongyu apatinibtreatmentefficientlydelaysbiochemicalonlyrecurrentovariancancerprogression
AT huangyake apatinibtreatmentefficientlydelaysbiochemicalonlyrecurrentovariancancerprogression
AT longling apatinibtreatmentefficientlydelaysbiochemicalonlyrecurrentovariancancerprogression
AT zhouli apatinibtreatmentefficientlydelaysbiochemicalonlyrecurrentovariancancerprogression
AT huangyan apatinibtreatmentefficientlydelaysbiochemicalonlyrecurrentovariancancerprogression
AT ganlei apatinibtreatmentefficientlydelaysbiochemicalonlyrecurrentovariancancerprogression
AT puaimin apatinibtreatmentefficientlydelaysbiochemicalonlyrecurrentovariancancerprogression
AT lisufen apatinibtreatmentefficientlydelaysbiochemicalonlyrecurrentovariancancerprogression
AT xierongkai apatinibtreatmentefficientlydelaysbiochemicalonlyrecurrentovariancancerprogression